Genocea Biosciences: Rises on introducing improved cancer therapy

Genocea Biosciences

13/05/2020 13:55

** Shares of biopharmaceuticals company  GNCA.O  rise 11.11%
to $3 premarket
    ** Company reports data on GEN-011, its T-cell therapy
designed to improve current limitations of TIL therapy in
treating cancers  urn:newsml:reuters.com:*:nGNX8gBJg4
    ** TIL cells, or tumor-infiltrating lymphocyte, can
recognize and kill cancer cells; in therapy, TILs removed from a
patient's tumor are grown in a lab, and then infused back into
the patient to help immune system kill cancers
    **  GEN-011 works in a similar manner but targets the tumors
more specifically and ensures greater breadth of coverage - GNCA
    ** Company expects to file Investigational New Drug
application with U.S. FDA within Q2 2020 and report initial
clinical data in first half of 2021
    ** GNCA shares up 30.43% this year, as of last close
    

 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 80 6749 6132;))